What is the appropriate dosing, duration, and contraindications for extended‑release melatonin in adults with insomnia?

Extended-Release Melatonin for Adult Insomnia

The American Academy of Sleep Medicine recommends AGAINST using melatonin (including extended-release formulations) for the treatment of chronic insomnia in adults due to insufficient evidence of efficacy. 1

Key Guideline Position

The most recent and authoritative AASM 2017 clinical practice guideline explicitly states a weak recommendation against melatonin for both sleep onset and sleep maintenance insomnia, based on trials of 2 mg doses 1. This represents a consensus position across multiple AASM guidelines from 2008 and 2017 2, which consistently cite "relative lack of efficacy and safety data" as the primary concern 2.

The Exception: Older Adults ≥55 Years

For patients aged 55 years and older specifically, prolonged-release melatonin 2 mg may be considered as first-line pharmacotherapy. 1, 3, 4

Dosing for Older Adults:

• Dose: 2 mg prolonged-release (PR) formulation
• Timing: 1-2 hours before desired bedtime (approximately 6 PM for 8 PM bedtime) 5
• Duration: Up to 3 months initially 4, 6
• Formulation specificity: Must be prolonged-release; immediate-release formulations are NOT recommended 4

The rationale is that melatonin production naturally decreases with age 5, and PR melatonin shows larger effect sizes in this population (large effect on objective sleep efficiency: 2.95% improvement, p<0.001) 7.

Why Standard Melatonin Is Not Recommended

The evidence reveals critical problems:

• Modest efficacy: Even PR melatonin shows only small-to-medium effect sizes in general adult populations (subjective sleep onset latency reduced by 6.3 minutes, objective by 5.05 minutes) 7
• Timing-dependent, not dose-dependent: Melatonin functions primarily as a chronobiotic (circadian regulator), not a hypnotic 8. Its effectiveness depends on proper timing relative to the patient's circadian phase, not on higher doses
• Formulation inconsistency: Over-the-counter preparations show substantial variability in actual melatonin content 8
• Diagnostic confusion: Circadian rhythm disorders are frequently misdiagnosed as primary insomnia, leading to inappropriate symptomatic treatment 8

Contraindications and Cautions

While melatonin has a favorable safety profile with mild, transient adverse events 9, avoid or use cautiously in:

• Pregnancy and nursing (general sedative/hypnotic precaution) 2
• Patients with depression (monitor for behavioral changes, though less concerning than with other hypnotics)
• Concurrent use with other CNS depressants (additive effects possible) 2
• Hepatic impairment (though less problematic than benzodiazepines)

Preferred Alternatives for General Adult Population

First-line treatment: Cognitive-behavioral therapy for insomnia (CBT-I) 1, 10, 4

If pharmacotherapy is needed after CBT-I failure:

1. Benzodiazepine receptor agonists (eszopiclone 2-3 mg, zolpidem 10 mg, zaleplon 10 mg) 1
2. Orexin receptor antagonists (daridorexant, suvorexant 10-20 mg) 1
3. Low-dose doxepin (3-6 mg) for sleep maintenance insomnia 1

These agents have demonstrated superior efficacy with moderate-to-low quality evidence supporting their use 1, 10.

Common Pitfalls to Avoid

• Using immediate-release melatonin: Rapidly absorbed and cleared, failing to maintain levels throughout the sleep period 11
• Supraphysiological dosing: Higher doses (>2 mg) do not improve efficacy and reflect misunderstanding of melatonin's mechanism 8
• Bedtime administration without circadian consideration: Melatonin should be timed 1-2 hours before desired sleep, not reflexively at bedtime 5
• Treating undiagnosed circadian rhythm disorders: Delayed sleep-wake phase disorder requires different timing strategies 8
• Long-term use without reassessment: Even in older adults, reassess after 3 months 4

Pharmacokinetic Considerations

Extended-release formulations demonstrate:

• Time to peak: 1.56 hours (vs. 0.6 hours for immediate-release) 11
• Elimination half-life: 1.63 hours (vs. 0.95 hours for immediate-release) 11
• Duration of elevated levels: Maintains levels >300 pg/mL for 6 hours 11
• Onset: Raises levels within 15 minutes 11

This profile better mimics endogenous nocturnal melatonin secretion 11.

Monitoring and Follow-Up

When PR melatonin is used in patients ≥55 years:

• Assess effectiveness at 1 week (subjective sleep quality should begin improving) 9
• Formal reassessment at 4 weeks (objective sleep parameters should show improvement) 9
• Consider discontinuation or alternative therapy if no response by 4 weeks
• Do not continue beyond 3 months without clear benefit and reassessment 4